Folliculin Regulates MTORC1/2 and WNT Pathways in Early Human Pluripotency
Overview
Authors
Affiliations
To reveal how cells exit human pluripotency, we designed a CRISPR-Cas9 screen exploiting the metabolic and epigenetic differences between naïve and primed pluripotent cells. We identify the tumor suppressor, Folliculin(FLCN) as a critical gene required for the exit from human pluripotency. Here we show that FLCN Knock-out (KO) hESCs maintain the naïve pluripotent state but cannot exit the state since the critical transcription factor TFE3 remains active in the nucleus. TFE3 targets up-regulated in FLCN KO exit assay are members of Wnt pathway and ESRRB. Treatment of FLCN KO hESC with a Wnt inhibitor, but not ESRRB/FLCN double mutant, rescues the cells, allowing the exit from the naïve state. Using co-immunoprecipitation and mass spectrometry analysis we identify unique FLCN binding partners. The interactions of FLCN with components of the mTOR pathway (mTORC1 and mTORC2) reveal a mechanism of FLCN function during exit from naïve pluripotency.
Cicchetti R, Basconi M, Litterio G, Mascitti M, Tamborino F, Orsini A Int J Mol Sci. 2024; 25(16).
PMID: 39201746 PMC: 11355026. DOI: 10.3390/ijms25169060.
Antagonistic Roles for MITF and TFE3 in Melanoma Plasticity.
Chang J, Campbell-Hanson K, Vanneste M, Bartschat N, Nagel R, Arnadottir A bioRxiv. 2024; .
PMID: 39026725 PMC: 11257520. DOI: 10.1101/2024.07.11.603140.
Influence of metabolic stress and metformin on synaptic protein profile in SH-SY5Y-derived neurons.
Yang A, Mohammad A, Finch M, Tsiani E, Spencer G, Necakov A Physiol Rep. 2023; 11(22).
PMID: 38010200 PMC: 10680579. DOI: 10.14814/phy2.15852.
Unveiling Novel Avenues in mTOR-Targeted Therapeutics: Advancements in Glioblastoma Treatment.
Singh S, Barik D, Lawrie K, Mohapatra I, Prasad S, Naqvi A Int J Mol Sci. 2023; 24(19).
PMID: 37834408 PMC: 10573615. DOI: 10.3390/ijms241914960.
Derivation of Naïve Human Embryonic Stem Cells Using a CHK1 Inhibitor.
Ware C, Jonlin E, Anderson D, Cavanaugh C, Hesson J, Sidhu S Stem Cell Rev Rep. 2023; 19(8):2980-2990.
PMID: 37702917 PMC: 10662141. DOI: 10.1007/s12015-023-10613-2.